Immunotherapeutic approaches for cancer therapy: An updated review

Artificial Cells, Nanomedicine and Biotechnology

Volumn 44, Issue 3, 2016, Pages 769-779

  Kazemi, Tohid ^a,b   Younesi, Vahid ^c   Jadidi Niaragh, Farhad ^c   Yousefi, Mehdi ^a,b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

cancer; cancer stem cell; dendritic cell; immunotherapy; monoclonal antibody; vaccination

Indexed keywords

ANTIBODIES; ANTIGENS; CELLS; CYTOLOGY; IMMUNE SYSTEM; MONOCLONAL ANTIBODIES; PATIENT TREATMENT; STEM CELLS; TUMORS; VACCINES;

CANCER; CANCER STEM CELLS; DENDRITIC CELLS; IMMUNOTHERAPY; VACCINATION;

DISEASES;

CANCER VACCINE; DENDRITIC CELL VACCINE; DNA VACCINE; HEAT SHOCK PROTEIN; IBRITUMOMAB TIUXETAN; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 2; IODINE 131; ISCOM; LIPOSOME; MONOCLONAL ANTIBODY; OKT 3; PEPTIDE VACCINE; PROGRAMMED DEATH 1 LIGAND 1; SIPULEUCEL T; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOSITUMOMAB; TRANSFORMING GROWTH FACTOR BETA; TRYPTOPHAN; TUMOR ANTIGEN; TUMOR CELL VACCINE; VASCULOTROPIN; VEDOTIN; VIROSOME; VIRUS VECTOR; WART VIRUS VACCINE; YTTRIUM 90; CANCER ANTIBODY;

ACTIVE IMMUNOTHERAPY; ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER STEM CELL; CELL THERAPY; CLONAL ANERGY; COMPLEMENT DEPENDENT CYTOTOXICITY; DNA IMMUNIZATION; EX VIVO STUDY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; IMMUNOSURVEILLANCE; INNATE IMMUNITY; INTRACELLULAR SIGNALING; MONOTHERAPY; MYCOBACTERIUM BOVIS BCG; PASSIVE IMMUNOTHERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SOMATIC MUTATION; TUMOR ESCAPE; TUMOR VOLUME; ANIMAL; IMMUNOLOGY; LYMPHOCYTE TRANSFUSION; NEOPLASMS; PROCEDURES; T LYMPHOCYTE; TRANSPLANTATION;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; HUMANS; LYMPHOCYTE TRANSFUSION; NEOPLASMS; T-LYMPHOCYTES;

EID: 84969916595     PISSN: 21691401     EISSN: 2169141X     Source Type: Journal    
DOI: 10.3109/21691401.2015.1019669     Document Type: Review

References (158)

1. D.I.Abrams, P.A.Volberding. 1986. Alpha interferon therapy of AIDS-associated Kaposi's sarcoma. Semin Oncol. 13:43–47.
2. S.Ahmed, K.R.Rai. 2003. Interferon in the treatment of hairy-cell leukemia. Best Pract Res Clin Haematol. 16:69–81.
3. S.Antonia, J.J.Mule, J.S.Weber. 2004. Current developments of immunotherapy in the clinic. Curr Opin Immunol. 16:130–136.
4. M.B.Atkins, M.T.Lotze, J.P.Dutcher, R.I.Fisher, G.Weiss, K.Margolin,. 1999. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 17:2105–2116.
5. M.P.Baker, H.M.Reynolds, B.Lumicisi, C.J.Bryson. 2010. Immunogenicity of protein therapeutics: The key causes, consequences and challenges. Self Nonself. 1:314–322.
6. S.Bao, Q.Wu, R.E.McLendon, Y.Hao, Q.Shi, A.B.Hjelmeland,. 2006. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 444:756–760.
7. S.K.Bhutia, S.K.Mallick, T.K.Maiti. 2010. Tumour escape mechanisms and their therapeutic implications in combination tumour therapy. Cell Biol Int. 34:553–563.
8. R.J.Binder, D.K.Han, P.K.Srivastava. 2000. CD91: a receptor for heat shock protein gp96. Nat Immunol. 1:151–155.
9. D.Boczkowski, S.K.Nair, J.H.Nam, H.K.Lyerly, E.Gilboa. 2000. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res. 60:1028–1034.
10. F.Bonifazi, A.De Vivo, G.Rosti, F.Guilhot, J.Guilhot, E.Trabacchi,. 2001. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood. 98:3074–3081.
11. C.A.Borrebaeck. 1989. Strategy for the production of human monoclonal antibodies using in vitro activated B cells. J Immunol Methods. 123:157–165.
12. M.Breccia, F.Lo-Coco. 2011. Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy. Expert Opin Biol Ther. 11: 225–234.
13. M.Burnet. 1957. Cancer—A Biological Approach: III. Viruses associated with neoplastic conditions. IV. Practical applications. Br Med J. 1:841.
14. I.J.Caley, M.R.Betts, D.M.Irlbeck, N.L.Davis, R.Swanstrom, J.A.Frelinger, R.E.Johnston. 1997. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J Virol. 71:3031–3038.
15. M.Cartellieri, M.Bachmann, A.Feldmann, C.Bippes, S.Stamova, R.Wehner,. 2010. Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol. 2010: 956304.
16. D.Chen, S.Koido, Y.Li, S.Gendler, J.Gong. 2000. T cell suppression as a mechanism for tolerance to MUC1 antigen in MUC1 transgenic mice. Breast Cancer Res Treat. 60:107–115.
17. M.S.Chen, W.A.Woodward, F.Behbod, S.Peddibhotla, M.P.Alfaro, T.A.Buchholz, J.M.Rosen. 2007. Wnt/β-catenin mediates radiation resistance of Sca1 + progenitors in an immortalized mammary gland cell line. J Cell Sci. 120:468–477.
18. Z.Chen, T.Moyana, A.Saxena, R.Warrington, Z.Jia, J.Xiang. 2001. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int J Cancer. 93:539–548.
19. A.T.Cheuk, L.Chan, B.Czepulkowski, S.A.Berger, H.Yagita, K.Okumura,. 2006. Development of a whole cell vaccine for acute myeloid leukaemia. Cancer Immunol Immunother. 55:68–75.
20. R.T.Costello, J.A.Gastaut, D.Olive. 1999. Tumor escape from immune surveillance. Arch Immunol Ther Exp (Warsz). 47:83–88.
21. M.L.Davila, C.C.Kloss, G.Gunset, M.Sadelain. 2013. CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS One. 8:e61338.
22. G.de Bruyn, A.J.Rossini, Y.L.Chiu, D.Holman, M.L.Elizaga, S.E.Frey,. 2004. Safety profile of recombinant canarypox HIV vaccines. Vaccine. 22:704–713.
23. C.De Giovanni, G.Nicoletti, L.Landuzzi, A.Astolfi, S.Croci, A.Comes,. 2004. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine. Cancer Res. 64:4001–4009.
24. M.L.Disis, T.A.Gooley, K.Rinn, D.Davis, M.Piepkorn, M.A.Cheever,. 2002. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol. 20:2624–2632.
25. J.J.Donnelly, B.Wahren, M.A.Liu. 2005. DNA vaccines: progress and challenges. J Immunol. 175:633–639.
26. J.Doorbar. 2006. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 110:525–541.
27. G.Dotti, B.Savoldo, M.Brenner. 2009. Fifteen years of gene therapy based on chimeric antigen receptors: “are we nearly there yet?”. Hum Gene Ther. 20:1229–1239.
28. G.Dranoff. 2003. GM-CSF-secreting melanoma vaccines. Oncogene. 22:3188–3192.
29. S.J.Draper, J.L.Heeney. 2010. Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol. 8:62–73.
30. G.P.Dunn, A.T.Bruce, H.Ikeda, L.J.Old, R.D.Schreiber. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 3:991–998.
31. J.P.Dutcher. 2011. High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard. Oncology (Williston Park). 25:427–428.
32. P.R.Ehrlich, F.Himmelweit. 1956. The collected papers of Paul Ehrlich. London:Pergamon Press.
33. M.A.G.Essers, A.Trumpp. 2010. Targeting leukemic stem cells by breaking their dormancy. Mol Oncol. 4:443–450.
34. M.Feili-Hariri, D.H.Falkner, P.A.Morel. 2005. Polarization of naive T cells into Th1 or Th2 by distinct cytokine-driven murine dendritic cell populations: implications for immunotherapy. J Leukoc Biol. 78:656–664.
35. G.Ferlazzo, C.Semino, G.M.Spaggiari, M.Meta, M.C.Mingari, G.Melioli. 2000. Dendritic cells efficiently cross-prime HLA class I-restricted cytolytic T lymphocytes when pulsed with both apoptotic and necrotic cells but not with soluble cell-derived lysates. Int Immunol. 12:1741–1747.
36. O.J.Finn. 2006. Human tumor antigens, immunosurveillance, and cancer vaccines. Immunol Res. 36:73–82.
37. O.J.Finn. 2008. Cancer immunology. N Engl J Med. 358:2704–2715.
38. O.J.Finn. 2012. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 23 Suppl 8:viii6–9.
39. S.Flynn, B.Stockinger. 2003. Tumor and CD4 T-cell interactions: tumor escape as result of reciprocal inactivation. Blood. 101:4472–4478.
40. I.H.Frazer, D.R.Lowy, J.T.Schiller. 2007. Prevention of cancer through immunization: Prospects and challenges for the 21st century. Eur J Immunol. 37 Suppl 1:S148–155.
41. D.I.Gabrilovich, H.L.Chen, K.R.Girgis, H.T.Cunningham, G.M.Meny, S.Nadaf,. 1996. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 2:1096–1103.
42. J.Galea-Lauri, J.W.Wells, D.Darling, P.Harrison, F.Farzaneh. 2004. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination. Cancer Immunol Immunother. 53:963–977.
43. M.A.Garcia-Marquez, A.Shimabukuro-Vornhagen, S.Theurich, M.von Bergwelt-Baildon. 2013. Vaccination with dendritic cell-tumor fusion cells in multiple myeloma patients: a promising strategy? Immunotherapy. 5:1039–1042.
44. J.Gong, N.Nikrui, D.Chen, S.Koido, Z.Wu, Y.Tanaka,. 2000. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol. 165:1705–1711.
45. J.W.Greiner, H.Zeytin, M.R.Anver, J.Schlom. 2002. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res. 62:6944–6951.
46. O.M.T.S.Group. 1985. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med. 313:337–342.
47. E.Q.Han, X.L.Li, C.R.Wang, T.F.Li, S.Y.Han. 2013. Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges. J Hematol Oncol. 6:47.
48. F.A.Harding, M.M.Stickler, J.Razo, R.B.DuBridge. 2010. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs. 2:256–265.
49. R.Harrop, M.W.Carroll. 2006. Viral vectors for cancer immunotherapy. Front Biosci. 11:804–817.
50. A.Hauschild. 2009. Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations? Curr Oncol. 16:3–6.
51. A.Heiser, P.Dahm, D.R.Yancey, M.A.Maurice, D.Boczkowski, S.K.Nair,. 2000. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol. 164:5508–5514.
52. P.R.Hess, D.Boczkowski, S.K.Nair, D.Snyder, E.Gilboa. 2006. Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen. Cancer Immunol Immunother. 55:672–683.
53. S.M.Huang, J.M.Bock, P.M.Harari. 1999. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 59:1935–1940.
54. F.H.Igney, P.H.Krammer. 2002. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol. 71:907–920.
55. Y.Iwai, M.Ishida, Y.Tanaka, T.Okazaki, T.Honjo, N.Minato. 2002. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 99:12293–12297.
56. S.A.Jacobs. 2007. Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma: current status and future prospects. Biologics. 1:215–227.
57. E.Jager, D.Jager, A.Knuth. 2002. Clinical cancer vaccine trials. Curr Opin Immunol. 14:178–182.
58. P.T.Jones, P.H.Dear, J.Foote, M.S.Neuberger, G.Winter. 1986. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature. 321:522–525.
59. C.T.Jordan, M.L.Guzman, M.Noble. 2006. Cancer stem cells. N Engl J Med. 355:1253–1261.
60. P.W.Kantoff, C.S.Higano, N.D.Shore, E.R.Berger, E.J.Small, D.F.Penson,. 2010. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 363:411–422.
61. M.H.Kershaw, J.A.Westwood, P.K.Darcy. 2013. Gene-engineered T cells for cancer therapy. Nat Rev Cancer. 13:525–541.
62. C.J.Kim, J.Cormier, M.Roden, L.Gritz, G.P.Mazzara, P.Fetsch,. 1998. Use of recombinant poxviruses to stimulate anti-melanoma T cell reactivity. Ann Surg Oncol. 5:64–76.
63. J.W.Kim, E.Wieckowski, D.D.Taylor, T.E.Reichert, S.Watkins, T.L.Whiteside. 2005. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res. 11:1010–1020.
64. K.J.Kim, B.Li, K.Houck, J.Winer, N.Ferrara. 1992. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors. 7:53–64.
65. R.Kim, M.Emi, K.Tanabe. 2007. Cancer immunoediting from immune surveillance to immune escape. Immunology. 121:1–14.
66. J.Kirkwood. 2002. Cancer immunotherapy: the interferon-α experience. Semin Oncol. 29:18–26.
67. G.Kohler, C.Milstein. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 256:495–497.
68. C.Kyi, M.A.Postow. 2014. Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett. 588:368–376.
69. P.H.Lambert, M.Liu, C.A.Siegrist. 2005. Can successful vaccines teach us how to induce efficient protective immune responses? Nat Med. 11:S54–62.
70. G.D.Lewis, I.Figari, B.Fendly, W.L.Wong, P.Carter, C.Gorman, H.M.Shepard. 1993. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother. 37:255–263.
71. H.Li, H.J.Jiang, M.Q.Ma, F.Wei, X.M.An, X.B.Ren. 2007. Vaccination with allogeneic GM-CSF gene-modified lung cancer cells: antitumor activity comparing with that induced by autologous vaccine. Cancer Biother Radiopharm. 22:790–798.
72. Y.Li, M.Bendandi, Y.Deng, C.Dunbar, N.Munshi, S.Jagannath,. 2000. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Blood. 96:2828–2833.
73. P.L.Lollini, F.Cavallo, P.Nanni, G.Forni. 2006. Vaccines for tumour prevention. Nat Rev Cancer. 6:204–216.
74. N.Lonberg. 2008. Fully human antibodies from transgenic mouse and phage display platforms. Curr Opin Immunol. 20:450–459.
75. M.Mackett, G.L.Smith, B.Moss. 1982. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A. 79:7415–7419.
76. M.J.Maeurer, S.M.Gollin, D.Martin, W.Swaney, J.Bryant, C.Castelli,. 1996. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest. 98:1633–1641.
77. A.L.Mellor, D.Munn, P.Chandler, D.Keskin, T.Johnson, B.Marshall,. 2003. Tryptophan catabolism and T cell responses. Adv Exp Med Biol. 527:27–35.
78. C.Mesa, L.E.Fernandez. 2004. Challenges facing adjuvants for cancer immunotherapy. Immunol Cell Biol. 82:644–650.
79. J.P.Meyer, R.Persad, D.A.Gillatt. 2002. Use of bacille Calmette-Guerin in superficial bladder cancer. Postgrad Med J. 78:449–454.
80. T.Meyer, C.Surber, L.E.French, E.Stockfleth. 2013. Resiquimod, a topical drug for viral skin lesions and skin cancer. Expert Opin Investig Drugs. 22:149–159.
81. C.Milazzo, V.L.Reichardt, M.R.Muller, F.Grunebach, P.Brossart. 2003. Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood. 101:977–982.
82. L.M.Minasian, R.J.Motzer, L.Gluck, M.Mazumdar, V.Vlamis, S.E.Krown. 1993. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol. 11:1368–1375.
83. R.S.Mittler, J.Foell, M.Mccausland, S.Strahotin, L.Niu, A.Bapat, L.B.Hewes. 2004. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer. Immunol Res. 29:197–208.
84. S.Mocellin, S.Mandruzzato, V.Bronte, M.Lise, D.Nitti. 2004. Part I: Vaccines for solid tumours. Lancet Oncol. 5:681–689.
85. S.Mocellin, F.M.Marincola, H.A.Young. 2005. Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol. 78:1043–1051.
86. A.E.Moran, M.Kovacsovics-Bankowski, A.D.Weinberg. 2013. The TNFRs OX40, 4–1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol. 25:230–237.
87. A.Nencioni, M.R.Muller, F.Grunebach, A.Garuti, M.C.Mingari, F.Patrone,. 2003. Dendritic cells transfected with tumor RNA for the induction of antitumor CTL in colorectal cancer. Cancer Gene Ther. 10:209–214.
88. F.O.Nestle, G.Tonel, A.Farkas. 2005. Cancer vaccines: the next generation of tools to monitor the anticancer immune response. PLoS Med. 2:e339.
89. M.S.Neuberger, G.T.Williams, E.B.Mitchell, S.S.Jouhal, J.G.Flanagan, T.H.Rabbitts. 1985. A hapten-specific chimaeric IgE antibody with human physiological effector function. Nature. 314:268–270.
90. A.M.Neville, A.M.Mackay, J.Westwood, C.Turberville, D.J.Laurence. 1975. Human tumour-associated and tumour-specific antigens: some concepts in relation to clinical oncology. J Clin Pathol Suppl (Assoc Clin Pathol). 6:102–112.
91. K.D.Newman, P.Elamanchili, G.S.Kwon, J.Samuel. 2002. Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. J Biomed Mater Res. 60:480–486.
92. C.Newstead. 1998. Assessment of risk of cancer after renal transplantation. Lancet. 351:610–611.
93. L.V.Nguyen, R.Vanner, P.Dirks, C.J.Eaves. 2012. Cancer stem cells: an evolving concept. Nat Rev Cancer. 12:133–143.
94. D.T.O’Hagan, M.Singh, J.B.Ulmer. 2006. Microparticle-based technologies for vaccines. Methods. 40:10–19.
95. V.Oldfield, G.M.Keating, C.M.Perry. 2005. Imiquimod: in superficial basal cell carcinoma. Am J Clin Dermatol. 6:195–200; discussion 201–202.
96. R.K.Oldham. 1983. Monoclonal antibodies in cancer therapy. J Clin Oncol. 1:582–590.
97. S.C.Pageau. 2009. Denosumab. MAbs. 1:210–215.
98. K.Palucka, J.Banchereau. 2013. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 39:38–48.
99. D.M.Pardoll. 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
100. G.Parmiani, L.Pilla, C.Maccalli, V.Russo. 2011. Autologous versus allogeneic cell-based vaccines? Cancer J. 17:331–336.
101. B.Pasche. 2001. Role of transforming growth factor beta in cancer. J Cell Physiol. 186:153–168.
102. G.Q.Phan, J.C.Yang, R.M.Sherry, P.Hwu, S.L.Topalian, D.J.Schwartzentruber,. 2003. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 100:8372–8377.
103. F.Pijpers, R.Faint, N.Saini. 2005. Therapeutic cancer vaccines. Nat Rev Drug Discov. 4:623–624.
104. G.J.Randolph, K.Inaba, D.F.Robbiani, R.M.Steinman, W.A.Muller. 1999. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity. 11:753–761.
105. M.E.Reff, K.Carner, K.S.Chambers, P.C.Chinn, J.E.Leonard, R.Raab,. 1994. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 83:435–445.
106. M.J.Rico, R.P.Hall3rd. 1989. Anti-idiotypic antibodies as vaccine candidates. The immune network. Arch Dermatol. 125:271–275.
107. C.Riether, C.Schurch, A.F.Ochsenbein. 2012. Modulating CD27 signaling to treat cancer. Oncoimmunology. 1:1604–1606.
108. C.Riether, C.Schurch, A.F.Ochsenbein. 2013. From “magic bullets” to specific cancer immunotherapy. Swiss Med Wkly. 143:w13734.
109. H.L.Robinson, T.M.Pertmer. 2000. DNA vaccines for viral infections: basic studies and applications. Adv Virus Res. 55:1–74.
110. L.D.Roman, S.Wilczynski, L.I.Muderspach, A.F.Burnett, A.O’Meara, J.A.Brinkman,. 2007. A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. Gynecol Oncol. 106:558–566.
111. S.A.Rosenberg, J.C.Yang, N.P.Restifo. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 10:909–915.
112. S.A.Rosenberg, Y.Zhai, J.C.Yang, D.J.Schwartzentruber, P.Hwu, F.M.Marincola,. 1998. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst. 90:1894–1900.
113. F.J.Rutar, S.C.Augustine, M.S.Kaminski, R.L.Wahl, J.A.Siegel, D.Colcher. 2001. Feasibility and safety of outpatient Bexxar therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members. Clin Lymphoma. 2:164–172.
114. M.Sadelain, R.Brentjens, I.Riviere. 2013. The basic principles of chimeric antigen receptor design. Cancer Discov. 3:388–398.
115. F.Salazar-Onfray. 1999. Interleukin-10: a cytokine used by tumors to escape immunosurveillance. Med Oncol. 16:86–94.
116. R.Salgia, T.Lynch, A.Skarin, J.Lucca, C.Lynch, K.Jung,. 2003. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol. 21:624–630.
117. L.Sanchez-Perez, T.Kottke, R.M.Diaz, A.Ahmed, J.Thompson, H.Chong,. 2005. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Cancer Res. 65:2009–2017.
118. J.-E.Sarry, K.Murphy, R.Perry, P.V.Sanchez, A.Secreto, C.Keefer,. 2011. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. J Clin Invest. 121:384.
119. V.Schächinger, B.Assmus, M.B.Britten, J.Honold, R.Lehmann, C.Teupe,. 2004. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarctionfinal one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol. 44:1690–1699.
120. D.A.Schaer, J.T.Murphy, J.D.Wolchok. 2012. Modulation of GITR for cancer immunotherapy. Curr Opin Immunol. 24:217–224.
121. T.H.Schreiber, L.Raez, J.D.Rosenblatt, E.R.Podack. 2010. Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art. Semin Immunol. 22:105–112.
122. A.Schulenburg, H.Herrmann, H.Karlic, I.Mirkina, R.Hubmann, S.Laffer,. 2010. Neoplastic stem cells: current concepts and clinical perspectives. Crit Rev Oncol Hematol. 76:79–98.
123. A.M.Scott, J.P.Allison, J.D.Wolchok. 2012. Monoclonal antibodies in cancer therapy. Cancer Immun. 12:14.
124. N.H.Segal, D.W.Parsons, K.S.Peggs, V.Velculescu, K.W.Kinzler, B.Vogelstein, J.P.Allison. 2008. Epitope landscape in breast and colorectal cancer. Cancer Res. 68:889–892.
125. G.P.Smith. 1985. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science. 228:1315–1317.
126. M.R.Smith, F.Saad, R.Coleman, N.Shore, K.Fizazi, B.Tombal,. 2012. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 379:39–46.
127. R.E.Sobol. 2006. The rationale for prophylactic cancer vaccines and need for a paradigm shift. Cancer Gene Ther. 13:725–731.
128. P.K.Srivastava. 2005. Immunotherapy for human cancer using heat shock protein-peptide complexes. Curr Oncol Rep. 7:104–108.
129. R.M.Steinman, J.Banchereau. 2007. Taking dendritic cells into medicine. Nature. 449:419–426.
130. F.K.Stevenson. 2004. DNA vaccines and adjuvants. Immunol Rev. 199:5–8.
131. F.K.Stevenson, C.H.Ottensmeier, P.Johnson, D.Zhu, S.L.Buchan, K.J.Mccann,. 2004. DNA vaccines to attack cancer. Proc Natl Acad Sci U S A. 101 Suppl 2:14646–14652.
132. S.Strand, P.R.Galle. 1998. Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications. Mol Med Today. 4:63–68.
133. M.M.Strioga, T.Felzmann, D.J.PowellJr., V.Ostapenko, N.T.Dobrovolskiene, M.Matuskova,. 2013. Therapeutic dendritic cell-based cancer vaccines: the state of the art. Crit Rev Immunol. 33:489–547.
134. Z.Tabi, S.Man. 2006. Challenges for cancer vaccine development. Adv Drug Deliv Rev. 58:902–915.
135. D.C.Tang, M.Devit, S.A.Johnston. 1992. Genetic immunization is a simple method for eliciting an immune response. Nature. 356:152–154.
136. A.Tarhini, E.Lo, D.R.Minor. 2010. Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm. 25:601–613.
137. D.C.Taussig, F.Miraki-Moud, F.Anjos-Afonso, D.J.Pearce, K.Allen, C.Ridler,. 2008. Anti-CD38 antibody–mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood. 112:568–575.
138. D.D.Taylor, C.G.Taylor, C.G.Jiang, P.H.Black. 1988. Characterization of plasma membrane shedding from murine melanoma cells. Int J Cancer. 41:629–635.
139. J.L.Teeling, R.R.French, M.S.Cragg, J.van Den Brakel, M.Pluyter, H.Huang,. 2004. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 104:1793–1800.
140. M.Theobald, J.Biggs, D.Dittmer, A.J.Levine, L.A.Sherman. 1995. Targeting p53 as a general tumor antigen. Proc Natl Acad Sci U S A. 92:11993–11997.
141. J.M.Timmerman, D.K.Czerwinski, T.A.Davis, F.J.Hsu, C.Benike, Z.M.Hao,. 2002. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 99:1517–1526.
142. P.L.Triozzi, K.O.Allen, R.R.Carlisle, M.Craig, A.F.Lobuglio, R.M.Conry. 2005. Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma. Clin Cancer Res. 11: 4168–4175.
143. C.Vaklavas, A.Forero-Torres. 2012. Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Ther Adv Hematol. 3:209–225.
144. A.M.Vazquez, A.M.Hernandez, A.Macias, E.Montero, D.E.Gomez, D.F.Alonso,. 2012. Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data. Front Oncol. 2:150.
145. D.S.Vinay, B.S.Kwon. 2012. Immunotherapy of cancer with 4–1BB. Mol Cancer Ther. 11:1062–1070.
146. T.Vu, F.X.Claret. 2012. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front Oncol. 2:62.
147. T.L.Whiteside. 2005. Tumour-derived exosomes or microvesicles: another mechanism of tumour escape from the host immune system? Br J Cancer. 92:209–211.
148. K.C.Wollert, G.P.Meyer, J.Lotz, S.Ringes-Lichtenberg, P.Lippolt, C.Breidenbach,. 2004. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 364:141–148.
149. K.Yaddanapudi, R.A.Mitchell, J.W.Eaton. 2013. Cancer vaccines: Looking to the future. Oncoimmunology. 2:e23403.
150. N.Yajima, R.Yamanaka, T.Mine, N.Tsuchiya, J.Homma, M.Sano,. 2005. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res. 11:5900–5911.
151. X.D.Yang, X.C.Jia, J.R.Corvalan, P.Wang, C.G.Davis, A.Jakobovits. 1999. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 59:1236–1243.
152. C.Yee. 2013. Adoptive T-cell therapy for cancer: boutique therapy or treatment modality? Clin Cancer Res. 19:4550–4552.
153. M.Yu, O.J.Finn. 2006. DNA vaccines for cancer too. Cancer Immunol Immunother. 55:119–130.
154. C.S.Zent, C.R.Secreto, B.R.Laplant, N.D.Bone, T.G.Call, T.D.Shanafelt,. 2008. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk Res. 32:1849–1856.
155. G.Zhou, Z.Lu, J.D.Mccadden, H.I.Levitsky, A.L.Marson. 2004. Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J Exp Med. 200:1581–1592.
156. H.Zhou, Y.Luo, J.F.Lo, C.D.Kaplan, M.Mizutani, N.Mizutani,. 2005. DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor. Proc Natl Acad Sci U S A. 102:10846–10851.
157. W.Zou. 2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 5:263–274.
158. C.M.zum Buschenfelde, C.Hermann, B.Schmidt, C.Peschel, H.Bernhard. 2002. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res. 62:2244–2247.